Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

34 bytes added, 08:40, 5 November 2017
m
no edit summary
*[https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf NCCN Guidelines - Myelodysplastic Syndromes]
=UntreatedFirst-line therapy=
==Azacitidine monotherapy {{#subobject:3235e3|Regimen=1}}==
# Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [http://ascopubs.org/doi/abs/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28486043 PubMed]
=Maintenanceafter first-line therapy=
==Azacitidine monotherapy {{#subobject:2471cc|Regimen=1}}==
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu